Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

Background Omacetaxine mepesuccinate is indicated in adults with chronic myeloid leukemia resistant and/or intolerant to ≥ 2 tyrosine kinase inhibitor treatments. This phase I study assessed the disposition, elimination, and safety of 14C-omacetaxine in patients with solid tumors. Methods The study...

Full description

Bibliographic Details
Main Authors:	Nijenhuis, Cynthia M., Hellriegel, Edward, Beijnen, Jos H., Hershock, Diane, Huitema, Alwin D. R., Lucas, Luc, Mergui-Roelvink, Marja, Munteanu, Mihaela, Rabinovich-Guilatt, Laura, Robertson, Philmore, Rosing, Hilde, Spiegelstein, Ofer, Schellens, Jan H. M.
Format:	Online
Language:	English
Published:	Springer US 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007276/

Similar Items

Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy
by: Dubbelman, Anne-Charlotte, et al.
Published: (2013)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
by: Keizer, Ron J, et al.
Published: (2015)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
by: Keizer, Ron J., et al.
Published: (2011)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
by: van der Noll, Ruud, et al.
Published: (2015)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
by: Lü, Shuqing, et al.
Published: (2014)

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment
by: Lotte van Andel, et al.
Published: (2018-07-01)

Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
by: Chen, Yaoyu, et al.
Published: (2014)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
by: Crombag, Marie-Rose B.S., et al.
Published: (2016)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
by: Rabinovich‐Guilatt, L., et al.
Published: (2015)

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses
by: Wetzler, M, et al.
Published: (2015)

Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
by: Kurtin, Sandra E., et al.
Published: (2013)

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
by: van Hasselt, J. G. Coen, et al.
Published: (2014)

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”
by: van Hasselt, J. G. Coen, et al.
Published: (2015)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
by: Darwish, Mona, et al.
Published: (2014)

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
by: Jager, N. G. L., et al.
Published: (2012)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
by: Jager, Nynke GL, et al.
Published: (2013)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
by: de Vries Schultink, Aurelia H. M., et al.
Published: (2015)

Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
by: Kulkarni, Hemant, et al.
Published: (2012)

The Role of Bile Acid Excretion in Atherosclerotic Coronary Artery Disease
by: Charach, Gideon, et al.
Published: (2012)

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin
by: van Hasselt, JGC, et al.
Published: (2015)

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin
by: van Hasselt, JGC, et al.
Published: (2015)

Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice
by: Chen, Yaoyu, et al.
Published: (2009)

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
by: Nemunaitis, John, et al.
Published: (2012)

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment
by: de Vries Schultink, A. H. M., et al.
Published: (2016)

Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
by: Keizer, Ron J., et al.
Published: (2011)

Treatment Individualization in Colorectal Cancer
by: van Geel, Robin M. J. M., et al.
Published: (2015)

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
by: Soto, Elena, et al.
Published: (2010)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
by: van der Noll, R., et al.
Published: (2015)

Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B-cell lymphoma cells
by: ZHANG, LINA, et al.
Published: (2016)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
by: Hendrikx, J J M A, et al.
Published: (2014)

Urinary pseudouridine excretion in myelomatosis.
by: Sørensen, S. H., et al.
Published: (1985)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
by: Schellens, J. H., et al.
Published: (1996)

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection
by: Kip, A. E., et al.
Published: (2016)

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
by: Darwish, Mona, et al.
Published: (2015)

Excretion of Immunoglobulins in Burkitt's Lymphoma
by: McFarlane, H., et al.
Published: (1970)

THE EXCRETION OF CARBON DIOXIDE BY FROG NERVE
by: Parker, G. H.
Published: (1925)

THE NUMERICAL LAWS GOVERNING THE RATE OF EXCRETION OF UREA AND CHLORIDES IN MAN : I. AN INDEX OF UREA EXCRETION AND THE NORMAL EXCRETION OF UREA AND CHLORIDES.
by: McLean, Franklin C.
Published: (1915)

Excreting and non-excreting grasses exhibit different salt resistance strategies
by: Moinuddin, Muhammad, et al.
Published: (2014)

THE CAUSE OF THE EXCESSIVE CALCIUM EXCRETION THROUGH THE FECES IN INFANTILISM
by: McCrudden, F. H., et al.
Published: (1913)

Assessment of Performance of Manufacturing Procedures in a Unit for Production of Investigational Anticancer Agents, Using a Mixed Effects Analysis
by: van der Schoot, S. C., et al.
Published: (2007)